AbCellera’s Blockbuster Drug Not Available in Canada?

Posted on by in General

Abcellera is Canada’s most valuable biotech company. It licensed its antibody for COVID 19 called bamlanivimab to Eli Lilly. This licensing deal has lead to monumental royalties of US$233M in revenue and US$119M in net profit. A winner beyond words.

Bamlanivimab is used to reduce hospitalizations by up to 80% in recently diagnosed patients and reduces the risk of getting infected in high risk environments such as nursing homes by 80%.

AbCellera has a block buster drug on the move with approval in 15 countries, exept it is NOT available in Canada.

That is a head scratcher! 15 regulatory agencies approve the drug. Canada took a pass. Health Canada did not approve the drug.

So does that mean that rationing is more important than saving lives in Canada.

Raymond Rupert patient advocate and health system disruptor.